medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 5

<< Back Next >>

Ann Hepatol 2017; 16 (5)

Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis

Pereira JG, Erotides ST, Bansho ETO, Morato EF, Pinheiro JT, Muraro-Wildner L, Bazzo ML, Dantas-Corrêa EB, Schiavon LL, Narciso-Schiavon JL

Language: English
References: 36
Page: 780-787
PDF size: 163.11 Kb.


ABSTRACT

Background: Despite the circulating levels of PTX3 were related to the severity of various diseases, there are no studies investigating its role in patients with liver cirrhosis. We aimed to study PTX3 levels in patients with liver cirrhosis. Material and methods. A prospective cohort study included 130 patients hospitalized for acute decompensation of liver cirrhosis, 29 stable cirrhotic outpatients and 32 healthy controls evaluated in a tertiary hospital in Southern Brasil. Results. The median PTX3 level was significantly higher in stable cirrhotic patients compared to controls (2.6 vs. 1.1 ng/mL; p ‹ 0.001), hospitalized cirrhotic patients compared to controls (3.8 vs. 1.1 ng/mL; p ‹ 0.001), and hospitalized cirrhotic patients compared to stable cirrhotic patients (3.8 vs. 2.6 ng/ mL; p = 0.001). A positive correlation was found between PTX3 and serum creatinine (r = 0.220; p = 0.012), Chronic Liver Failure - Sequential Organ Failure Assessment score (CLIF-SOFA) (r = 0.220; p = 0.010), MELD (r = 0.279; p = 0.001) and Child-Pugh score (r = 0.224; p = 0.010). Significantly higher levels of PTX3 were observed in patients on admission with ACLF (8.9 vs. 3.1 ng/mL; p ‹ 0.001) and MELD score ≥ 20 (6.6 vs. 3.4 ng/mL; p = 0.002). Death within 90 days occurred in 30.8% of patients and was associated with higher levels of PTX3 (5.3 vs. 3.4 ng/mL; p = 0.009). The probability of Kaplan-Meier survival was 77.0% in patients with PTX-3 ‹ 5.3 ng mL (upper tercile) and 53.5% in those with PTX3 ≥ 5.3 ng/mL (p = 0.002). Conclusion. These results indicate the potential for use of PTX3 as an inflammatory biomarker for the prognosis of patients with hepatic cirrhosis.


REFERENCES

  1. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol 2015; 49: 690-6. [PMID: 25291348 DOI: 10.1097/ MCG.0000000000000208].

  2. Yoon YH, Yi HY. Liver cirrhosis mortality in the United States, 1970-2003: Surveillance Report No. 75. Arlington: National Institute on Alcohol Abuse and Alcoholism 2006.

  3. Kim HY, Kim CW, Choi JY, Lee CD, Lee SH, Kim MY, Jang BK, et al. Complications requiring hospital admission and causes of in-hospital death over time in alcoholic and nonalcoholic cirrhosis patients. Gut Liver 2016; 10: 95-100. [PMID: 26087788 DOI: 10.5009/gnl14363].

  4. Silva PE, Fayad L, Lazzarotto C, Ronsoni MF, Bazzo ML, Colombo BS, Dantas-Correa EB, et al. Single-centre validation of the EASL-CLIF consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis. Liver Int 2015; 35: 1516-23. [PMID: 24840673 DOI: 10.1111/liv.12597].

  5. Zhang J, Shan L, Koussih L, Redhu NS, Halayko AJ, Chakir J, Gounni AS. Pentraxin 3 (PTX3) Expression in Allergic Asthmatic Airways: Role in Airway Smooth Muscle Migration and Chemokine Production. Rojas M (Ed.). PLoS ONE 2012; 7: e34965. [PMID: 22529962 DOI: 10.1371/ journal.pone.0034965].

  6. Cieslik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity 2012; 45: 119-28. [PMID: 21988562 DOI: 10.3109/ 08916934.2011.611549].

  7. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, Fratini M, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 196-202. [PMID 10606983 DOI: 10.1046/j.1365-2249.2000.01110.x].

  8. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008; 20: 538-44. [PMID: 18579363 DOI: 10.1016/j.coi.2008.05.004].

  9. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The Long Pentraxin 3 and Its Role in Autoimmunity. Semin Arthritis Rheum 2009; 39: 38-54. [PMID: 18614204 DOI: 10.1016/j.semarthrit.2008.03.006].

  10. Rajkovic I, Denes A, Allan SM, Pinteaux E. Emerging roles of the acute phase protein pentraxin-3 during central nervous system disorders. J Neuroimmunol 2016; 292: 27-33. [PMID: 26943955 DOI: 10.1016/j.jneuroim.2015.12.007].

  11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40. [PMID: 2841893 DOI: 10.1016/0196- 6553(88)90053-3].

  12. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47. [PMID: 20002027 DOI: 10.1111/j.1365-2036.2009.04211.x].

  13. Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879-85. [PMID: 12740346 DOI: 10.1136/gut.52.6.879].

  14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70. [PMID: 11172350 DOI: 10.1053/jhep.2001.22172].

  15. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al; CANONIC Study Investigators of the EASLCLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37, 1437 e1421-1429. [PMID: 23474284 DOI: 10.1053/ j.gastro.2013.02.042].

  16. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, et al; Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-54. [PMID: 15477419 DOI: 10.1161/ 01.CIR.0000145167.30987.2E].

  17. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Bárány P, Axelsson J, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2: 889-97. [PMID: 17702732 DOI: 10.2215/CJN.00870207].

  18. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008; 36: 2302-8. [PMID: 18596636 DOI: 10.1097/ CCM.0b013e3181809aaf].

  19. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29:1404-7. [PMID: 11445697 DOI: 10.1097/ 00003246-200107000-00017].

  20. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, et al. Role of pentraxin 3 (PTX3) and C reactive protein as markers of inflammation in ARDS [abstract]. Intensive Care Med 2005; 31(S1): S216.

  21. Fischer J, Silva TE, Silva PES, Colombo BS, Wildner LM, Bazzo ML, Frode TS, et al. Circulating interleukin 6, 10 and 17 as prognostic markers in patients with liver cirrhosis. In: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, 2015, San Francisco. Hepatology 2015; 62: 1220A.

  22. Le Moine O, Deviere J, Devaster JM, Crusiaux A, Durand F, Bernuau J, Goldman M, et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994; 20: 819-24. [PMID: 7930484 DOI: 10.1016/S0168- 8278(05)80155-2].

  23. Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS, Oh MD, et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis 2005; 51: 227-30. [PMID: 15808312 DOI: 10.1016/j.diagmicrobio.2004.11.014].

  24. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 2005; 146: 347-51. [PMID: 16310518 DOI: 10.1016/ j.lab.2005.08.005].

  25. Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, Schiavon LL, et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013; 12: 431-9. [PMID: 23813138].

  26. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12. [PMID: 12813013 DOI: 10.1172/JCI200318921].

  27. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66. [PMID: 15771574 DOI: 10.1146/ annurev.immunol.23.021704.115756].

  28. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007; 292: 1039-49. [PMID: 17277044 DOI: 10.1152/ajplung. 00490.2006].

  29. Soares AC, Souza DG, Pinho V, Vieira AT, Nicoli JR, Cunha FQ, Mantovani A, et al. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes Infect 2006; 8: 1321-9. [PMID: 16697676 DOI: 10.1016/ j.micinf.2005.12.017].

  30. Dias AA, Goodman AR, Dos Santos JL, Gomes RN, Altmeyer A, Bozza PT, Horta MF, et al. TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J Leukoc Biol 2001; 69: 928-36. [PMID: 11404378].

  31. Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: Another link between inflammation and clotting activation. J Leukoc Biol 2004; 76: 203-9. [PMID: 15226367 DOI: 10.1189/jlb.1003528].

  32. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-82. [PMID: 19560225 DOI: 10.1016/ j.jhep.2009.04.017].

  33. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl. 1): S1-S12. [PMID: 22300459 DOI: 10.1016/S0168-8278(12)60002-6].

  34. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-72. [PMID: 15123075 DOI: 10.1016/ j.bpg.2003.10.005].

  35. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach J, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201. [PMID: 15664244 DOI: 10.1016/ j.jhep.2004.10.019].

  36. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, Jalan R. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-40. [PMID: 17680644 DOI: 10.1002/hep.21737].




2020     |     www.medigraphic.com